CJC-1295

What it is

CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue — a growth-hormone secretagogue developed to stimulate endogenous GH release.S3

Marketed as

CJC-1295 is marketed for "anti-aging" and body recomposition — more growth hormone, muscle gain, fat loss, and better sleep — usually sold stacked with ipamorelin. These are marketing claims, not established effects; long-term human data are lacking.

Regulatory status (US)

CJC-1295 is not FDA-approved for any indication.S1S3 On FDA's compounding framework it appears in the "nominated but withdrawn" portion of Category 2, and it is not on the July 2026 PCAC agenda; no scheduled PCAC review has been verified.S1

Around the world

CJC-1295 is not approved as a medicine anywhere in the world.S1 Across the US, EU, UK, and elsewhere it exists only as a research chemical or off-label compounded product, not a licensed drug.S1S2

Evidence

Human therapeutic evidence is limited; CJC-1295 remains a developmental compound rather than an approved medicine. It has appeared in analytical literature as an ingredient identified in unregulated or seized preparations, underscoring its gray-market circulation.S3

Anti-doping

As a GHRH analogue / GH secretagogue, CJC-1295 is prohibited at all times under WADA S2 (peptide hormones, growth factors, related substances and mimetics).S2

Safety

FDA's general Category 2 concerns apply: possible immunogenicity for some routes, impurity/characterization complexity, and limited human safety data.S1

What's changing

No PCAC review of CJC-1295 has been verified as scheduled; its US status remains "not approved, nomination withdrawn" pending any future FDA action.S1